These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 30554109)

  • 1. Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?
    Solomon HV; Cates KW; Li KJ
    Psychiatry Res; 2019 Jan; 271():604-613. PubMed ID: 30554109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication.
    Walden LM; Brandl EJ; Tiwari AK; Cheema S; Freeman N; Braganza N; Kennedy JL; Müller DJ
    Psychiatry Res; 2019 Sep; 279():111-115. PubMed ID: 29699889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol for a pharmacogenetic study of antidepressants: characterization of drug-metabolizing profiles of cytochromes CYP2D6 and CYP2C19 in a Sardinian population of patients with major depressive disorder.
    Pinna M; Manchia M; Pisanu C; Pinna F; Paribello P; Carta A; Meloni A; Conversano C; Del Zompo M; Mola F; Squassina A; Carpiniello B
    Psychiatr Genet; 2021 Oct; 31(5):186-193. PubMed ID: 34282075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.
    Jessel CD; Mostafa S; Potiriadis M; Everall IP; Gunn JM; Bousman CA
    Pharmacogenet Genomics; 2020 Sep; 30(7):145-152. PubMed ID: 32433340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis.
    Li D; Pain O; Fabbri C; Wong WLE; Lo CWH; Ripke S; Cattaneo A; Souery D; Dernovsek MZ; Henigsberg N; Hauser J; Lewis G; Mors O; Perroud N; Rietschel M; Uher R; Maier W; Baune BT; Biernacka JM; Bondolfi G; Domschke K; Kato M; Liu YL; Serretti A; Tsai SJ; Weinshilboum R; ; McIntosh AM; Lewis CM
    Transl Psychiatry; 2024 Jul; 14(1):296. PubMed ID: 39025838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder.
    Brandl EJ; Tiwari AK; Zhou X; Deluce J; Kennedy JL; Müller DJ; Richter MA
    Pharmacogenomics J; 2014 Apr; 14(2):176-81. PubMed ID: 23545896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer.
    Brown JT; Schneiderhan M; Eum S; Bishop JR
    Pharmacogenomics; 2017 May; 18(7):601-605. PubMed ID: 28470111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
    de Leon J; Susce MT; Murray-Carmichael E
    Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting.
    Bousman CA; Jaksa P; Pantelis C
    Pharmacogenet Genomics; 2017 Nov; 27(11):387-393. PubMed ID: 28777243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of CYP2C19 and CYP2D6 genotyping to guide antidepressant use in a large rural health system.
    Petry NJ; Van Heukelom J; Schultz AJ; Jacobsen K; Baye JF; Mills S; Figueroa DM; Massmann A
    Am J Health Syst Pharm; 2024 Aug; 81(16):723-732. PubMed ID: 38546726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic testing among patients with depression in a US managed care population.
    Anderson HD; Thant TM; Kao DP; Crooks KR; Mendola ND; Aquilante CL
    Clin Transl Sci; 2022 Jul; 15(7):1644-1653. PubMed ID: 35385214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
    Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
    Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?
    Taranu A; Colle R; Gressier F; El Asmar K; Becquemont L; Corruble E; Verstuyft C
    Pharmacogenomics; 2017 May; 18(7):639-650. PubMed ID: 28480819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
    Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
    J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of CYP2D6 and CYP2C19 metabolizer status with switching and discontinuing antidepressant drugs: an exploratory study.
    Brouwer JMJL; Wardenaar KJ; Nolte IM; Liemburg EJ; Bet PM; Snieder H; Mulder H; Cath DC; Penninx BWJH
    BMC Psychiatry; 2024 May; 24(1):394. PubMed ID: 38797832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implementation of preemptive pharmacogenomics in psychiatry: Τhe "PREPARE" study.
    Tsermpini EE; Skokou M; Ferentinos P; Georgila E; Gourzis P; Assimakopoulos K; Patrinos GP;
    Psychiatriki; 2020; 31(4):341-351. PubMed ID: 33361064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomic testing for CYP2C19 and CYP2D6 in cyclic vomiting syndrome.
    Patel M; Partovi O; Karrento K; Garacchi Z; Balasubramanian G; Venkatesan T
    Neurogastroenterol Motil; 2024 Jan; 36(1):e14705. PubMed ID: 37953495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.
    Quaranta S; Dupouey J; Colle R; Verstuyft C
    Therapie; 2017 Apr; 72(2):311-318. PubMed ID: 28237405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study.
    Honeycutt DC; Blom TJ; Ramsey LB; Strawn JR; Bruns KM; Welge JA; Patino LR; Singh MK; DelBello MP
    J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):42-51. PubMed ID: 38377518
    [No Abstract]   [Full Text] [Related]  

  • 20. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.
    Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
    Clin Chem; 2005 Feb; 51(2):376-85. PubMed ID: 15590749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.